GURUFOCUS.COM » STOCK LIST » USA » NYSE » Pfizer Inc (NYSE:PFE) » Definitions » Cash Flow from Operations
Switch to:

Pfizer Cash Flow from Operations

: $31,454 Mil (TTM As of Jun. 2022)
View and export this data going back to 1951. Start your Free Trial

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Jun. 2022, Pfizer's Net Income From Continuing Operations was $9,877 Mil. Its Depreciation, Depletion and Amortization was $1,175 Mil. Its Change In Working Capital was $-2,766 Mil. Its cash flow from deferred tax was $-1,140 Mil. Its Cash from Discontinued Operating Activities was $-5 Mil. Its Asset Impairment Charge was $27 Mil. Its Stock Based Compensation was $287 Mil. And its Cash Flow from Others was $715 Mil. In all, Pfizer's Cash Flow from Operations for the three months ended in Jun. 2022 was $8,170 Mil.


Pfizer Cash Flow from Operations Historical Data

The historical data trend for Pfizer's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Flow from Operations
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16,802.00 15,827.00 12,588.00 14,403.00 32,580.00

Pfizer Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Cash Flow from Operations Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,299.00 10,829.00 5,914.00 6,541.00 8,170.00

Pfizer Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Pfizer's Cash Flow from Operations for the fiscal year that ended in Dec. 2021 is calculated as:

Pfizer's Cash Flow from Operations for the quarter that ended in Jun. 2022 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $31,454 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pfizer  (NYSE:PFE) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Pfizer's net income from continuing operations for the three months ended in Jun. 2022 was $9,877 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Pfizer's depreciation, depletion and amortization for the three months ended in Jun. 2022 was $1,175 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Pfizer's change in working capital for the three months ended in Jun. 2022 was $-2,766 Mil. It means Pfizer's working capital declined by $2,766 Mil from Mar. 2022 to Jun. 2022 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Pfizer's cash flow from deferred tax for the three months ended in Jun. 2022 was $-1,140 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Pfizer's cash from discontinued operating Activities for the three months ended in Jun. 2022 was $-5 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Pfizer's asset impairment charge for the three months ended in Jun. 2022 was $27 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Pfizer's stock based compensation for the three months ended in Jun. 2022 was $287 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Pfizer's cash flow from others for the three months ended in Jun. 2022 was $715 Mil.


Pfizer Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Pfizer's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Pfizer logo
Address
235 East 42nd Street, New York, NY, USA, 10017
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Executives
Denton David M officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD MOORESVILLE NC 28117
Pao William officer: Executive Vice President C/O CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Mcdermott Michael officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET 235 EAST 42ND STREET NY 10017
Malik Aamir officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE MURRAY HILL NJ 07921
Sahni Payal officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY 235 EAST 42ND ST. NEW YORK NY 10017
Desmond-hellmann Susan director 513 PARNASSUS AVENUE S126 SAN FRANCISCO CA 94143
Hockfield Susan director GENERAL ELECTRIC COMPANY 41 FARNSWORTH STREET BOSTON MA 02210
Damico Jennifer B. officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY 235 EAST 42ND STREET NEW YORK NY 10017
Quincey James director THE COCA-COLA COMPANY ONE COCA-COLA PLAZA ATLANTA GA 30313
Gottlieb Scott director MOLECULAR INSIGHT PHARMACEUTICALS 160 SECOND STREET CAMBRIDGE MA 02142
Fonseca Lidia officer: Executive Vice President 358 SOUTH MAIN STREET BURLINGTON NC 27215
Goettler Michael officer: Group President 1000 MYLAN BOULEVARD CANONSBURG PA 15317
Rogers Dawn officer: Executive Vice President 235 EAST 42ND STREET NEW YORK NY 10017
Littman Dan R. director ATTN: CORPORATE SECRETARY PFIZER INC. 235 E. 42ND ST NEW YORK NY 10017

Pfizer Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)